DK2906718T3 - Fremgangsmåde til diagnose, prognose og behandling af prostatakræftmetastase under anvendelse af c-maf - Google Patents

Fremgangsmåde til diagnose, prognose og behandling af prostatakræftmetastase under anvendelse af c-maf Download PDF

Info

Publication number
DK2906718T3
DK2906718T3 DK13821939.9T DK13821939T DK2906718T3 DK 2906718 T3 DK2906718 T3 DK 2906718T3 DK 13821939 T DK13821939 T DK 13821939T DK 2906718 T3 DK2906718 T3 DK 2906718T3
Authority
DK
Denmark
Prior art keywords
progestion
maf
prostate
diagnosis
procedure
Prior art date
Application number
DK13821939.9T
Other languages
Danish (da)
English (en)
Inventor
Roger Gomis
Joel Jean-Mairet
Original Assignee
Inbiomotion Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inbiomotion Sl filed Critical Inbiomotion Sl
Application granted granted Critical
Publication of DK2906718T3 publication Critical patent/DK2906718T3/da

Links

Classifications

    • G01N33/57555
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/112Disease subtyping, staging or classification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82Translation products from oncogenes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/56Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
DK13821939.9T 2012-10-12 2013-10-09 Fremgangsmåde til diagnose, prognose og behandling af prostatakræftmetastase under anvendelse af c-maf DK2906718T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261713318P 2012-10-12 2012-10-12
PCT/IB2013/002866 WO2014057357A2 (en) 2012-10-12 2013-10-09 Method for the diagnosis, prognosis and treatment of prostate cancer metastasis

Publications (1)

Publication Number Publication Date
DK2906718T3 true DK2906718T3 (da) 2019-07-01

Family

ID=49998595

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13821939.9T DK2906718T3 (da) 2012-10-12 2013-10-09 Fremgangsmåde til diagnose, prognose og behandling af prostatakræftmetastase under anvendelse af c-maf

Country Status (13)

Country Link
US (4) US20140105918A1 (enExample)
EP (2) EP2906718B1 (enExample)
JP (3) JP6074049B2 (enExample)
KR (1) KR101872965B1 (enExample)
CN (1) CN104995313A (enExample)
AU (1) AU2016213773B2 (enExample)
BR (1) BR112015008255B1 (enExample)
CA (1) CA2888122A1 (enExample)
DK (1) DK2906718T3 (enExample)
ES (2) ES2906586T3 (enExample)
HK (1) HK1213946A1 (enExample)
MX (1) MX365421B (enExample)
WO (1) WO2014057357A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012045905A2 (es) 2010-10-06 2012-04-12 Fundació Privada Institut De Recerca Biomèdica Método para el diagnóstico, pronóstico y tratamiento de la metástasis de cáncer de mama
EP2650682A1 (en) 2012-04-09 2013-10-16 Fundació Privada Institut de Recerca Biomèdica Method for the prognosis and treatment of cancer metastasis
KR102226219B1 (ko) 2012-06-06 2021-03-10 펀다시오 인스티튜트 드 르세르카 바이오메디카 (아이알비 바르셀로나) 폐암 전이의 진단, 예후 및 치료 방법
JP6074049B2 (ja) 2012-10-12 2017-02-01 インバイオモーション エセ.エレ. c−MAFを用いた前立腺がん転移の診断、予後診断および処置のための方法
US10119171B2 (en) 2012-10-12 2018-11-06 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
US20160032399A1 (en) * 2013-03-15 2016-02-04 Inbiomotion S.L. Method for the Prognosis and Treatment of Renal Cell Carcinoma Metastasis
US20140314792A1 (en) 2013-03-15 2014-10-23 Institució Catalana De Recerca I Estudis Avançats Method for the diagnosis, prognosis and treatment of cancer metastasis
US11206976B2 (en) * 2014-10-16 2021-12-28 New York University Method and system for simultaneous decomposition of multiple hyperspectral datasets and signal recovery of unknown fluorophores in a biochemical system
BR112017012515A2 (en) 2014-12-11 2018-01-02 Inbiomotion S.L. binding members for human c-maf
US20180303830A1 (en) * 2015-06-22 2018-10-25 Thomas Jefferson University Cancers expressing ccr5 and methods of treatment of same
PL3458610T3 (pl) * 2016-05-25 2021-11-22 Inbiomotion S.L. Leczenie raka piersi w oparciu o status c-MAF
CZ2016821A3 (cs) * 2016-12-22 2018-07-04 České vysoké učení technické v Praze Kombinace pro radionuklidovou terapii pro použití jako léčivo
BR112020010192A2 (pt) 2017-11-22 2020-10-13 Inbiomotion S.L. tratamento terapêutico de câncer de mama com base no status de c-maf
TW202012637A (zh) * 2018-04-24 2020-04-01 瑞典商阿斯特捷利康公司 治療癌症之方法
WO2024130224A2 (en) * 2022-12-16 2024-06-20 Purdue Research Foundation Stapled peptides for sensitization of cancer to treatment
CN116287250B (zh) * 2023-01-18 2025-12-16 中山大学附属第七医院(深圳) 一种前列腺癌骨转移诊断、治疗和/或预后的标志物及其应用
CN119007946B (zh) * 2024-08-02 2025-02-07 连云港市第二人民医院(连云港市临床肿瘤研究所) 一种用于肿瘤患者的全病程智能化医疗管理系统

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE89314T1 (de) 1985-02-13 1993-05-15 Scios Nova Inc Menschlicher metallothionein ii-promotor in saeugetierexpressionssystemen.
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5256775A (en) 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
JP2000508895A (ja) 1996-04-05 2000-07-18 ザ ソールク インスチチュート フォア バイオロジカル スタディズ 哺乳動物系における外来遺伝子の発現を調節するためのホルモン媒介方法と、それに関連した産物
CA2274987C (en) 1996-12-23 2012-01-24 Immunex Corporation Ligand for receptor activator of nf-kappa b, ligand is member of tnf superfamily
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
US6274338B1 (en) 1998-02-24 2001-08-14 President And Fellows Of Harvard College Human c-Maf compositions and methods of use thereof
US6355623B2 (en) 1998-09-24 2002-03-12 Hopital-Sainte-Justine Method of treating IBD/Crohn's disease and related conditions wherein drug metabolite levels in host blood cells determine subsequent dosage
EE04911B1 (et) 1999-03-15 2007-10-15 Axys Pharmaceuticals, Inc. Ühend ja farmatseutiline kompositsioon proteaasi inhibiitoritena, nende kasutamine ning meetod selle ühendi valmistamiseks
TW404030B (en) 1999-04-12 2000-09-01 Siliconware Precision Industries Co Ltd Dual-chip semiconductor package device having malposition and the manufacture method thereof
US6287813B1 (en) 1999-04-23 2001-09-11 Cistronics Cell Technology Gmbh Antibiotic-based gene regulation system
US6525036B2 (en) 2000-01-06 2003-02-25 Merck & Co., Inc. Compounds and compositions as protease inhibitors
ATE348617T1 (de) 2000-02-16 2007-01-15 Astellas Pharma Inc Heilmittel gegen durch endothelin verursachte erkrankungen
US6750015B2 (en) 2000-06-28 2004-06-15 Kathryn B. Horwitz Progesterone receptor-regulated gene expression and methods related thereto
DK2087908T3 (en) 2001-06-26 2018-07-23 Amgen Inc ANTIBODIES AGAINST OPGL
GB0121033D0 (en) 2001-08-30 2001-10-24 Novartis Ag Organic compounds
AR036375A1 (es) 2001-08-30 2004-09-01 Novartis Ag Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos
KR100485271B1 (ko) 2002-01-16 2005-04-27 메타볼랩(주) 전사인자 c-maf의 전사 활성 억제제로서의 니발레놀및 그를 포함하는 약제학적 조성물
SE0201980D0 (sv) 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds
DE10235624A1 (de) 2002-08-02 2004-02-19 Aventis Pharma Deutschland Gmbh Endiandric acid H und ihre Derivate, Verfahren zu ihrer Herstellung und Verwendung derselben
WO2005026322A2 (en) 2003-09-11 2005-03-24 Clontech Laboratories, Inc. siRNA ENCODING CONSTRUCTS AND METHODS FOR USING THE SAME
AU2003286499A1 (en) 2003-10-17 2004-06-06 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Interference with c-maf function in multiple myeloma
JP4579581B2 (ja) * 2003-12-08 2010-11-10 株式会社グリーンペプタイド 副甲状腺ホルモン関連タンパク質のhla−a24またはhla−a2結合ペプチド
US20090048117A1 (en) 2003-12-18 2009-02-19 President And Fellows Of Harvard College Modulation of immune system function by modulation of polypeptide arginine methyltransferases
TW200526224A (en) 2003-12-22 2005-08-16 Alcon Inc Short form c-Maf transcription factor antagonists for treatment of glaucoma
EP1706137A2 (en) 2004-01-21 2006-10-04 Chiron Corporation M-csf muteins and uses thereof
CA2567942A1 (en) 2004-05-26 2005-12-08 Green Peptide Co., Ltd. Hla-a24- or hla-a2-binding peptide of parathyroid hormone-related protein
US20080131940A1 (en) 2004-06-25 2008-06-05 Robert Chiu Target Cell-Specific Short Interfering Rna and Methods of Use Thereof
WO2006135436A2 (en) 2004-10-22 2006-12-21 University Of Florida Research Foundation, Inc. Inhibition of gene expression and therapeutic uses thereof
EP3211086B1 (en) 2005-09-20 2021-06-09 Menarini Silicon Biosystems S.p.A. Methods and composition to generate unique sequence dna probes, labeling of dna probes and the use of these probes
US9134237B2 (en) 2005-09-20 2015-09-15 Janssen Diagnotics, LLC High sensitivity multiparameter method for rare event analysis in a biological sample
EP1969000A2 (en) 2005-12-06 2008-09-17 Centre National de la Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
JP5142288B2 (ja) * 2006-04-05 2013-02-13 公立大学法人横浜市立大学 前立腺癌の予後判定方法及びそのための診断薬
WO2008098351A1 (en) 2007-02-14 2008-08-21 University Health Network Treatment of d-cyclin mediated proliferative diseases and hemotological malignancies
EP1961825A1 (en) * 2007-02-26 2008-08-27 INSERM (Institut National de la Santé et de la Recherche Medicale) Method for predicting the occurrence of metastasis in breast cancer patients
US8623361B2 (en) 2007-05-24 2014-01-07 Ablynx N.V. Amino acid sequences directed against RANK-L and polypeptides comprising the same for the treatment of bone diseases and disorders
US20110123617A1 (en) 2007-10-18 2011-05-26 University Health Network Clioquinol for the treatment of hematological malignancies
EP2296654A4 (en) 2008-06-06 2012-04-18 Univ Health Network 8-HYDROXYCHINOLINE DERIVATIVES FOR THE TREATMENT OF CRUISING HEMATOLOGICAL DISEASES
EP2400851A4 (en) * 2009-02-25 2012-09-05 Merrion Res Iii Ltd COMPOSITION AND ACTIVE COMPOSITION OF BISPHOSPHONATES
WO2012045905A2 (es) 2010-10-06 2012-04-12 Fundació Privada Institut De Recerca Biomèdica Método para el diagnóstico, pronóstico y tratamiento de la metástasis de cáncer de mama
ES2379918B1 (es) * 2010-10-06 2013-05-10 Fundació Privada Institut De Recerca Biomèdica Método para el diagnóstico, pronóstico y tratamiento de la metástasis de cáncer de mama.
US20140162887A1 (en) 2011-02-04 2014-06-12 Bioarray Therapeutics, Inc. Methods of using gene expression signatures to select a method of treatment, predict prognosis, survival, and/or predict response to treatment
WO2012115885A1 (en) * 2011-02-22 2012-08-30 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Circulating biomarkers
EP2650682A1 (en) * 2012-04-09 2013-10-16 Fundació Privada Institut de Recerca Biomèdica Method for the prognosis and treatment of cancer metastasis
KR102226219B1 (ko) 2012-06-06 2021-03-10 펀다시오 인스티튜트 드 르세르카 바이오메디카 (아이알비 바르셀로나) 폐암 전이의 진단, 예후 및 치료 방법
US10119171B2 (en) 2012-10-12 2018-11-06 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
JP6074049B2 (ja) * 2012-10-12 2017-02-01 インバイオモーション エセ.エレ. c−MAFを用いた前立腺がん転移の診断、予後診断および処置のための方法
AU2014229505B2 (en) 2013-03-15 2020-02-27 Fundacio Institut De Recerca Biomedica (Irb Barcelona) Method for the prognosis and treatment of cancer metastasis
US20140314792A1 (en) 2013-03-15 2014-10-23 Institució Catalana De Recerca I Estudis Avançats Method for the diagnosis, prognosis and treatment of cancer metastasis
US20160032399A1 (en) 2013-03-15 2016-02-04 Inbiomotion S.L. Method for the Prognosis and Treatment of Renal Cell Carcinoma Metastasis
MX362041B (es) 2013-10-09 2019-01-07 Fundacio Inst De Recerca Biomedica Irb Barcelona Método para el pronóstico y tratamiento de cáncer metastásico de los huesos originado de cáncer de mama.
HUE058328T2 (hu) 2014-06-17 2022-07-28 Asherman Therapy S L Õssejtterápia endometriális patológiás állapotokban
BR112017012515A2 (en) 2014-12-11 2018-01-02 Inbiomotion S.L. binding members for human c-maf
PL3458610T3 (pl) 2016-05-25 2021-11-22 Inbiomotion S.L. Leczenie raka piersi w oparciu o status c-MAF
BR112020010192A2 (pt) 2017-11-22 2020-10-13 Inbiomotion S.L. tratamento terapêutico de câncer de mama com base no status de c-maf

Also Published As

Publication number Publication date
US20150362495A1 (en) 2015-12-17
CA2888122A1 (en) 2014-04-17
MX365421B (es) 2019-06-03
JP2016500517A (ja) 2016-01-14
ES2906586T3 (es) 2022-04-19
JP6074049B2 (ja) 2017-02-01
MX2015004610A (es) 2015-10-22
US20140105918A1 (en) 2014-04-17
JP2016105731A (ja) 2016-06-16
HK1213946A1 (zh) 2016-07-15
EP3553186B1 (en) 2021-11-17
WO2014057357A2 (en) 2014-04-17
AU2016213773B2 (en) 2018-06-07
JP6446381B2 (ja) 2018-12-26
AU2013328385A1 (en) 2015-05-07
US11041861B2 (en) 2021-06-22
BR112015008255B1 (pt) 2023-02-28
US20190242898A1 (en) 2019-08-08
WO2014057357A3 (en) 2014-05-30
KR101872965B1 (ko) 2018-06-29
EP2906718A2 (en) 2015-08-19
AU2016213773A1 (en) 2016-09-01
CN104995313A (zh) 2015-10-21
US11892453B2 (en) 2024-02-06
EP2906718B1 (en) 2019-05-15
US20220042997A1 (en) 2022-02-10
KR20150105297A (ko) 2015-09-16
ES2744244T3 (es) 2020-02-24
JP6636067B2 (ja) 2020-01-29
JP2018078911A (ja) 2018-05-24
EP3553186A1 (en) 2019-10-16
BR112015008255A2 (pt) 2017-11-28
US10114022B2 (en) 2018-10-30

Similar Documents

Publication Publication Date Title
DK2906718T3 (da) Fremgangsmåde til diagnose, prognose og behandling af prostatakræftmetastase under anvendelse af c-maf
DK2895621T3 (da) Fremgangsmåder og sammensætning til diagnosticering, prognose og behandling af neurologiske tilstande
BR112015000654A2 (pt) método de formação de imagem, aparelho de formação de imagem, e matéria gravada
DK2885010T3 (da) Fremgangsmåder til behandling med tauopati
PL2640375T3 (pl) Sposób leczenia nefropatii pokontrastowej
DK2897620T3 (da) Fremgangsmåde til behandling af cancer
DK3622883T3 (da) Indførerer til medicinsk indretning og fremgangsmåder til at indføre og anvende medicinske indretninger
DK3230736T3 (da) Fremgangsmåder til måling af ErbB-signaleringsvejsaktivitet til at diagnosticere og behandle cancerpatienter
PT2683384E (pt) Métodos de tratamento de cancro utilizando 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidina-2,6-diona
BR112013013584A2 (pt) endoscópio, e, método
EP2812022A4 (en) CANCER TREATMENT AND MONITORING METHODS USING OX40 AGONISTS
DK2859017T3 (da) Antistoffer omfattrende stedsspecifikke ikke-naturlige aminosyrerester, fremgangsmåder til fremstilling heraf og fremgangsmåder til anvendelse heraf
DK2838900T3 (da) Forbindelser og fremgangsmåder til antiviral behandling
DK2663229T3 (da) Bi-hemisfærisk hjernebølgesystem og fremgangsmåde til at udføre bi-hemisfærisk hjernebølgemålinger
DK2815769T3 (da) Fam19a5 til anvendelse i diagnosticering og behandling af skader på centralnervesystemet
PT3412687T (pt) Métodos de tratamento de dlbcl
DK3444613T3 (da) Fremgangsmåder til diagnosticering og behandling af autisme
BR112014016108A2 (pt) método de tratamento de perda óssea alvelar
IL240560A0 (en) Compositions and methods for the diagnosis and treatment of tumor
DK2650049T3 (da) Hydrogenbehandlingskatalysator og fremgangsmåde til fremstilling af denne
BR112013011659A2 (pt) métodos de tratamento do câncer
BR112013022820A2 (pt) método de tratamento
PL2902787T3 (pl) Sposób oceny reakcji krzepnięcia krwi
DK2896694T3 (da) Saccharidoxidase og fremgangsmåde til fremstilling deraf og anvendelse deraf
DK3214226T3 (da) Fremgangsmåde og indretning til støjdæmpning